(Q34032263)

English

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Francesca Palandri

object named as

Francesca Palandri

1

0 references

Nicoletta Testoni

object named as

Nicoletta Testoni

8

0 references

Giorgina Specchia

object named as

Giorgina Specchia

16

0 references

Giuseppe Saglio

object named as

Giuseppe Saglio

18

0 references

Marilina Amabile

object named as

Marilina Amabile

5

0 references

Gianantonio Rosti

19

object named as

Gianantonio Rosti

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Fausto Castagnetti

2

object named as

Fausto Castagnetti

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Giovanni Martinelli

4

object named as

Giovanni Martinelli

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Gabriele Gugliotta

6

object named as

Gabriele Gugliotta

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Michele Baccarani

20

object named as

Michele Baccarani

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Massimo Breccia

9

object named as

Massimo Breccia

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

13

object named as

Bruno Martino

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Ilaria Iacobucci

3

object named as

Ilaria Iacobucci

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

17

object named as

Fabrizio Pane

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Giovanna Rege Cambrin

12

object named as

Giovanna Rege-Cambrin

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

10

object named as

Monica Bocchia

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

7

object named as

Angela Poerio

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Monica Crugnola

11

object named as

Monica Crugnola

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

14

object named as

Ivana Pierri

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Franca Radaelli

15

object named as

Franca Radaelli

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

19 March 2010

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

95

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1415-1419

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

5 July 2018

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

5 July 2018

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

5 July 2018

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

5 July 2018

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

5 July 2018

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

5 July 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

5 July 2018

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

5 July 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

5 July 2018

Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

5 July 2018

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

29 October 2018

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

29 October 2018

IFNalpha activates dormant haematopoietic stem cells in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

29 October 2018

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

29 October 2018

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

29 October 2018

Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

29 October 2018

IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

29 October 2018

Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

29 October 2018

Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2913092

29 October 2018

Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha

1 reference

https://pubmed.ncbi.nlm.nih.gov/20305139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20305139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/20305139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon

1 reference

https://pubmed.ncbi.nlm.nih.gov/20305139

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2009.021246

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34032263&oldid=1954116473"